D. E. Shaw & Co. Inc. Buys New Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

D. E. Shaw & Co. Inc. bought a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 105,130 shares of the biotechnology company's stock, valued at approximately $1,129,000. D. E. Shaw & Co. Inc. owned approximately 0.12% of Anavex Life Sciences at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AVXL. Cetera Investment Advisers bought a new position in shares of Anavex Life Sciences during the 4th quarter valued at approximately $150,000. Ameriprise Financial Inc. grew its stake in shares of Anavex Life Sciences by 5.1% in the 4th quarter. Ameriprise Financial Inc. now owns 66,810 shares of the biotechnology company's stock worth $718,000 after buying an additional 3,243 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Anavex Life Sciences by 1.6% in the 4th quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company's stock worth $7,592,000 after buying an additional 10,938 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Anavex Life Sciences in the 4th quarter worth about $495,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock valued at $36,000 after buying an additional 1,708 shares in the last quarter. Institutional investors own 31.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on AVXL shares. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th. HC Wainwright reaffirmed a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research note on Monday, April 7th.

Anavex Life Sciences Trading Up 0.7%

Shares of AVXL traded up $0.05 during trading hours on Thursday, reaching $7.63. 747,992 shares of the company traded hands, compared to its average volume of 1,225,702. The stock's fifty day moving average price is $8.57 and its 200 day moving average price is $9.09. The firm has a market cap of $651.39 million, a price-to-earnings ratio of -13.87 and a beta of 0.82. Anavex Life Sciences Corp. has a 12-month low of $3.51 and a 12-month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. During the same quarter in the previous year, the business earned ($0.13) EPS. On average, research analysts forecast that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.